The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
Abstract
Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More importantly, target-mediated drug disposition (TMDD) introduces a saturable, dose- and concentration-dependent component of clearance that no power-law regression can capture.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“At low concentrations, target-mediated clearance can dominate; at high concentrations, the target is saturated and linear, FcRn-mediated elimination dominates [47,50].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“A practical constraint in biologics first-in-human modelling is that not all of these disposition parameters can be identified simultaneously. FcRn-mediated linear clearance and central volume of distribution generally scale reliably from non-human primate data and can be estimated with reasonable confidence, whereas TMDD parameters such as target baseline concentration, target turnover, and”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“For biologics in particular, this also recognizes that not all parameters are simultaneously identifiable: FcRn-mediated linear clearance and central volume can be carried from non-human primate data, whereas poorly identifiable TMDD parameters are fixed to in vitro or literature values rather than estimated [50,51] (Section 4.5).”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
Protein Sorting by Transport Vesicles
Rothman, J. E., & Wieland, F. T. (1996) · Science · doi:10.1126/science.272.5259.227 · Cited by 1,153
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Comparison of four basic models of indirect pharmacodynamic responses
Dayneka, N. L., Garg, V., & Jusko, W. J. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061691 · Cited by 821
Self-citationClozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Recycling receptors: the round-trip itinerary of migrant membrane proteins
Brown, M. S., Anderson, R. G. W., & Goldstein, J. L. (1983) · Cell · doi:10.1016/0092-8674(83)90052-1 · Cited by 587
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Phase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Pharmacologic target-mediated drug disposition
Levy, G. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.134 · Cited by 332
Clinical Pharmacokinetics of Interferons
Wills, R. J. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199019050-00003 · Cited by 247
Weber, C., Schmitt, R., Birnboeck, H., Hopfgartner, G., van Marle, S. P., Peeters, P. A. M., Jonkman, J. H. G., & Jones, C.-R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90127-7 · Cited by 205
Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon-β in Healthy Male Volunteers
SALMON, P., LE COTONNEC, J.-Y., GALAZKA, A., ABDUL-AHAD, A., & DARRAGH, A. (1996) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1996.16.759 · Cited by 165
Sun, Y.-N., & Jusko, W. J. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970414z · Cited by 162
Self-citationPharmacodynamic modeling of time-dependent transduction systems
Mager, D. E., & Jusko, W. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.118244 · Cited by 145
Self-citationSharma, A., Ebling, W. F., & Jusko, W. J. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980171q · Cited by 132
Self-citationPastan, I., & Willingham, M. (1985) · Springer eBooks · doi:10.1007/978-1-4615-6904-6_1 · Cited by 121
Pharmacokinetics and Pharmacodynamics of IFN-β1a in Healthy Volunteers
Buchwalder, P.-A., Buclin, T., Trinchard, I., Munafo, A., & Biollaz, J. (2000) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900050163226 · Cited by 119
Weber, C., Gasser, R., & Gérard Hopfgartner, D. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15230-0 · Cited by 104
Weber, C., Schmitt, R., Birnboeck, H., Gérard Hopfgartner, D., Eggers, H., Meyer, J., van Marle, S., Visscher, H. W., & Jonkman, J. H. G. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008344 · Cited by 95
Chiang, J., Gloff, C. A., YOSHIZAWA, C. N., & Williams, G. J. (1993) · Pharmaceutical Research · doi:10.1023/a:1018902120023 · Cited by 89
Pharmacokinetics of repeated single oral doses of enalapril maleate (mk‐421) in normal volunteers
Till, A. E., Gomez, H. J., Hichens, M., Bolognese, J. A., McNabb, W. R., Brooks, B. A., Noormohamed, F. H., & Lant, A. F. (1984) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510050309 · Cited by 88
Sugiyama, Y., & Hanano, M. (1989) · Pharmaceutical Research · doi:10.1023/a:1015905331391 · Cited by 84
Dose‐dependent pharmacokinetics: Experimental observations and theoretical considerations
Lin, J. H. (1994) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510150102 · Cited by 82
Pastan, I., & Willingham, M. C. (1985) · Springer eBooks · doi:10.1007/978-1-4615-6904-6 · Cited by 62
Alam, J. J., Goelz, S. E., Rioux, P. P., Scaramucci, J., Jones, W. E., McAllister, A., Campion, M., & Rogge, M. C. (1997) · Pharmaceutical Research · doi:10.1023/a:1012128406432 · Cited by 57
Cheng, H., & Jusko, W. J. (1988) · Pharmaceutical Research · doi:10.1023/a:1015960806202 · Cited by 55
Self-citationEffect of saturable binding on the pharmacokinetics of drugs: a simulation
Øie, S., Guentert, T. W., & Tozer, T. N. (1980) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1980.tb12971.x · Cited by 45
Pharmacokinetics of an ACE inhibitor, S-9780, in man: Evidence of tissue binding
Lees, K. R., Kelman, A. W., Reid, J. L., & Whiting, B. (1989) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01071348 · Cited by 39
Intracellular pathways and mechanisms of sorting in receptor-mediated endocytosis
Shepherd, V. L. (1989) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(89)80011-2 · Cited by 35
Veng‐Pedersen, P., & Gillespie, W. R. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751202 · Cited by 35
Endothelin Receptor Antagonists: Current Status and Perspectives
Clozel, M. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200000002-00015 · Cited by 26
Dose-Dependent Pharmacokinetics of the Aldose Reductase Inhibitor Imirestat in Man
Brazzell, R. K., Mayer, P. R., DOBBS, R. E., McNamara, P. J., Teng, R., & Slattery, J. T. (1991) · Pharmaceutical Research · doi:10.1023/a:1015850911382 · Cited by 20
Saturable Tissue Binding and Imirestat Pharmacokinetics in Rats
Chien, J. Y., Banfield, C. R., Brazzell, R. K., Mayer, P. R., & Slattery, J. T. (1992) · Pharmaceutical Research · doi:10.1023/a:1015880011131 · Cited by 20
Pharmacokinetics and Metabolism of Therapeutic Cytokines
Gloff, C. A., & Wills, R. J. (1992) · Pharmaceutical biotechnology · doi:10.1007/978-1-4899-2329-5_5 · Cited by 19
Mathematical Modeling of Receptor-Mediated Endocytosis
Klausner, R. D., van Renswoude, J., Harford, J. B., Wofsy, C., & Goldstein, B. (1985) · Springer eBooks · doi:10.1007/978-1-4615-6904-6_9 · Cited by 15
Pharmacokinetics of Capacity-Limited Tissue Distribution of Methicillin in Rabbits
Gengo, F. M., Schentag, J. J., & Jusko, W. J. (1984) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600730703 · Cited by 14
Self-citationSnoeck, E., Jacqmin, P., Peer, A. V., & Danhof, M. (1999) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1023/a:1020943029130 · Cited by 12
MacFadyen, R., Lees, K. R., & Reid, J. L. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04119.x · Cited by 9
Research works printed but not linked: 3
- D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles (1997).
- W. J. Jusko. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics, Applied Therapeutics, Inc., Vancouver, 1992, Ch. 2.
- J. G. Wagner. A new generalized nonlinear pharmacokinetic model and its implications. In J. G. Wagner (ed.), Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1971, pp. 302–317.
Cited by
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Shah, D. K., & Betts, A. M. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9232-2 · Cited by 422
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Metadata
- Authors
- Mager, D. E., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2001-12
- Volume
- 28
- Issue
- 6
- Pages
- 507-532
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- OpenAlex
- W28215347
- Cited by
- 605
- References
- 40
- Citations by year
- 2026: 40 · 2025: 27 · 2024: 30 · 2023: 32 · 2022: 31 · 2021: 31 · 2020: 40 · 2019: 37 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 41 · 2014: 31 · 2013: 36 · 2012: 32
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 57980, R01GM057980)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- target-mediated drug disposition, nonlinear pharmacokinetics, receptor-mediated endocytosis, pharmacokinetic modeling, dose-dependent clearance, drug elimination, bosentan, interferon beta-1a, enzyme inhibitors, receptor antagonists
- MeSH terms
- Bosentan, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Fluorenes, Humans, Hydantoins, Male, Models, Chemical, Pharmacokinetics, Sulfonamides, Drug Delivery Systems, Interferon-beta, Nonlinear Dynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.